TITLE

Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials

AUTHOR(S)
Vakil, Nimish; Laine, Loren; Talley, Nicholas J.; Zakko, Salam F.; Tack, Jan; Chey, William D.; Kralstein, Jeffrey; Earnest, David L.; Ligozio, Gregory; Cohard-Radice, Marielle
PUB. DATE
August 2008
SOURCE
American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p1906
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a selective serotonin type 4 receptor agonist, in patients with FD. METHODS: Two identical multicenter, double-blind, randomized, placebo-controlled trials enrolled women ≥18 yr with recurring mid-upper abdominal discomfort characterized by postprandial fullness, early satiety, and/or bloating. Patients were randomized to tegaserod 6 mg b.i.d. or placebo. Two patient-reported primary variables were assessed: percentage of days with satisfactory symptom relief, and symptom severity using the composite average daily severity score (CADSS). RESULTS: In total, 2,667 women were randomized with no differences between trials in terms of recruitment method, Helicobacter pylori status, heartburn, or medication use. Mean percentage of days with satisfactory symptom relief for tegaserod versus placebo in Trial 1: 32.2% versus 26.6% (95% CI of treatment difference 2.82, 9.27; P < 0.01), Trial 2: 31.9% versus 29.4% (95% CI of treatment difference −0.21, 6.53; P= 0.066). Mean CADSS in Trial 1: 3.14 versus 3.35 (95% CI of treatment difference −0.29, −0.10; P < 0.0001), Trial 2: 3.15 versus 3.23 (95% CI of treatment difference −0.18, 0.01; P= 0.094). Meta-analysis showed significant benefit for both end points: increase in days with satisfactory relief 4.6% (95% CI 2.29, 6.96); decrease in CADSS 0.14 (95% CI 0.21, 0.07). Treatment effect was greater in patients with severe baseline symptoms. Diarrhea requiring study discontinuation was more common with tegaserod than placebo (4.1% vs 0.3%). CONCLUSIONS: Some improvement in dysmotility-like FD was observed with tegaserod treatment. The clinical implication of this improvement is uncertain.
ACCESSION #
33545330

 

Related Articles

  • Influence of Helicobacter pylori infection on in vitro responsiveness of gastric fundus to agonists and to stimulation of enteric nerves in Mongolian gerbils. Takehara, Yusuke; Mizuta, Yohei; Isomoto, Hajime; Ohnita, Ken; Yoshimura, Masaya; Nakamura, Takashi; Takeshima, Fuminao; Omagari, Katsuhisa; Murase, Kunihiko; Murata, Ikuo; Taniyama, Kohtaro; Kohno, Shigeru // Journal of Gastroenterology;2002, Vol. 37 Issue 8, p589 

    Background. It has recently been proposed that disturbed gastric adaptive relaxation may play a role in functional dyspepsia (FD). However, the effect of Helicobacter pylori infection, which may be one of multiple factors associated with FD, on gastric relaxation is not clear. The aim of this...

  • Helicobacter pylori Eradication Treatment Does Not Benefit Patients With Nonulcer Dyspepsia. Froehlich, F.; Gonvers, J. J.; Wietlishach, V.; Burnand, B.; Hildebrand, P.; Schneider, C.; Saraga, E.; Beglinger, C.; Vader, J. P. // American Journal of Gastroenterology;Aug2001, Vol. 96 Issue 8, p2329 

    OBJECTIVES: The aim of this study was to assess the still controversial role of treatment of Helicobacter pylori (H. pylori) infection in patients with nonulcer dyspepsia. METHODS: We conducted a double-blind. randomized placebo- controlled. multicenter trial comparing the efficacy of 7...

  • Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Koelz, H.R.; Arnold, R.; Stolte, M.; Fischer, M.; Blum, A.L. // Gut;Jan2003, Vol. 52 Issue 1, p40 

    Background: Previous studies on the treatment of Helicobacter pylori infection in functional dyspepsia have shown little, if any, effect on dyspeptic symptoms. However, whether such treatment might be of benefit in patients resistant to acid inhibitors has not been formally tested. Aim: The...

  • Helicobacter pylori LPS as an activator of T lymphocytes. Rudnicka, W.; Jarosinska, A.; Bak-Romaniszyn, L.; Moran, A.; Malecka, I. Planeta; Wadstrom, T.; Chmiela, M. // Gut;Sep2002 Supplement 2, Vol. 51, pA24 

    A role of LPS in the infections from Helicobacter pylori (H.p.) is still poorly known. In this study, we examined proliferative response of peripheral blood mononuclear leukocytes (PBML) from the children with chronic dyspepsia to H.p LPS in the presence and absence of IL-2 as a T cell factor....

  • Empiric approach to dyspepsia: test and treat strategy vs PPI treatment. A randomized controlled study. Maes, G.; de Nucci, C.; Mechise, A.; Balzano, A. // Gut;Sep2002 Supplement 2, Vol. 51, pA92 

    Reduction in the endoscopic workload by means of case selection based on empiric therapies has been advocated in order to reduce the costs for dyspepsia. The present study compares the efficacy of the "H. pylori — Hptest and treat strategy" with an empiric omeprazole trial. Methods: 219...

  • Effect of Helicobacter pylori eradication in Iranian patients with functional dyspepsia: a prospective, randomized, placebo-controlled trial. Yazdanbod, Abbas; Salimian, Sina; Habibzadeh, Shahram; Hooshyar, Afshin; Maleki, Nasrollah; Norouzvand, Maryam // Archives of Medical Science;Oct2015, Vol. 11 Issue 5, p964 

    Introduction: Whether patients with functional dyspepsia (FD) should receive Helicobacter pylori (H. pylori) eradication therapy remains controversial. The objective of this trial was to evaluate the effect of H. pylori eradication therapy on dyspeptic symptoms of patients with...

  • Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermehylation. Chan, A. O. O.; Peng, J. Z.; Lam, S. K.; Lai, K. C.; Yuen, M. F.; Cheung, H. K. L.; Kwong, Y. L.; Rashid, A.; Chan, C. K.; Wong, B. C.-Y. // Gut;Apr2006, Vol. 55 Issue 4, p463 

    Background: E-cadherin methylation is important in gastric carcinogenesis. Reversing hypermethylation may halt the carcinogenic process. We have previously reported that Helicobacter pylon infection is associated with E-cadherin methylation in chronic gastritis patients. Aim: To examine if...

  • Marked Rebound Acid Hypersecretion after Treatment with Ranitidine. El-Omar, E.; Banerjee, S.; Wirz, A.; Penman, I.; Ardill, J. E. S.; McColl, K. E. L. // American Journal of Gastroenterology;Feb1996, Vol. 91 Issue 2, p355 

    Objectives: Dyspeptic symptoms frequently recur rapidly after withdrawal of H2 antagonists, and this might be related to rebound acid hypersecretion. We have studied this phenomenon in healthy volunteers with and without Helicobacter pylori infection. Methods: Basal and...

  • Management of Helicobacter pylori infection. Harris, Adam; Misiewicz, J J // BMJ: British Medical Journal (International Edition);11/3/2001, Vol. 323 Issue 7320, p1047 

    Discusses management of Helicobacter pylori infection in patients with dyspepsia with or without endoscopic abnormalities. Eradication treatment for duodenal ulcer resulting from H pylori infection; Diagnosis and treatment of gastric ulcers; Interaction between H pylori and gastro-oesophageal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics